Clinical Trials Logo

Immunoglobulin A Nephropathy clinical trials

View clinical trials related to Immunoglobulin A Nephropathy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05200871 Completed - Clinical trials for Focal Segmental Glomerulosclerosis

Humanistic Burden of (FSGS) Focal Segmental Glomerulosclerosis and IgAN (Immunoglobulin A Nephropathy)

HONUS
Start date: February 5, 2022
Phase:
Study type: Observational

The aim of this observational study is to assess humanistic burden among adults and children/adolescents with FSGS and IgAN as well as the burden and impact for patient care-partners in six countries (United States [US], United Kingdom [UK], France, Germany, Italy and Spain).

NCT ID: NCT04287985 Completed - Clinical trials for Immunoglobulin A Nephropathy

Safety and Efficacy Study of VIS649 for IgA Nephropathy

Start date: July 20, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of VIS649 in participants with immunoglobulin A (IgA) Nephropathy (IgAN)

NCT ID: NCT03719443 Completed - IgA Nephropathy Clinical Trials

First in Human Study to Assess Safety of VIS649 in Healthy Subjects

Start date: October 9, 2018
Phase: Phase 1
Study type: Interventional

This is a phase 1, randomized, placebo-controlled, double-blind, single ascending dose study of IV VIS649 in healthy subjects. VIS649 is a monoclonal immunoglobulin G2 (IgG2) antibody targeting the B-cell growth factor APRILL. The study will enroll up to 45 subjects and will be conducted in up to 5 sequential dosing cohorts at four different dose levels, enrolling 9 subjects per cohort. Subjects will be randomized to VIS649 or placebo in a ratio of 7:2 (7 active, 2 placebo). Safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from the initial cohorts will be assessed.

NCT ID: NCT02384317 Completed - Clinical trials for Immunoglobulin A Nephropathy

Open-Label Study to Evaluate Safety and Efficacy of CCX168 in Subjects With IGA Nephropathy on Stable RAAS Blockade

Start date: March 27, 2015
Phase: Phase 2
Study type: Interventional

The primary safety objective of this study is to evaluate the safety and tolerability of CCX168 in subjects with IgAN on background supportive therapy with a maximally tolerated dose of RAAS blockade. The primary efficacy objective is to evaluate the efficacy of CCX168 based on an improvement in proteinuria.

NCT ID: NCT01838239 Completed - Healthy Subjects Clinical Trials

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN) and in healthy subjects. The hypothesis is that measuring variation among individuals and changes in response to omega-3 fatty acids comprehensively by using metabolomics will help to identify those individuals who are responders and those who are non-responders to omega-3 fatty acids as an anti-inflammatory intervention.